Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Other financing activities (2019 - 2025)

Benitec Biopharma's Other financing activities history spans 7 years, with the latest figure at $2.2 million for Q1 2025.

  • For Q1 2025, Other financing activities changed N/A year-over-year to $2.2 million; the TTM value through Mar 2025 reached $5.2 million, up 74.6%, while the annual FY2024 figure was $5.9 million, 215.25% up from the prior year.
  • Other financing activities for Q1 2025 was $2.2 million at Benitec Biopharma, up from $2000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $3.0 million in Q3 2023 and bottomed at $2000.0 in Q4 2024.
  • The 5-year median for Other financing activities is $2.1 million (2022), against an average of $1.9 million.
  • The largest YoY upside for Other financing activities was 58.59% in 2023 against a maximum downside of 58.59% in 2023.
  • A 5-year view of Other financing activities shows it stood at $1.6 million in 2021, then increased by 17.92% to $1.9 million in 2022, then soared by 58.59% to $3.0 million in 2023, then plummeted by 99.93% to $2000.0 in 2024, then skyrocketed by 112150.0% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Other financing activities are $2.2 million (Q1 2025), $2000.0 (Q4 2024), and $2.9 million (Q2 2024).